TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: 24-h ABPM
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: vascular structure and function of large and small arteries
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: percentage of fibrine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of Participants With Successful Pulmonary Vein Isolation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Pharmacokinetics of BMS-540215
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Chronic post-surgical pain scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Treatment decisions more consistent with preferences
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Breast cancer treatment knowledge
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Certainty about treatment choice
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in nausea
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean of blood loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: PSA level in blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: The rate of postoperative complications (including infections)
Endpoint domain: Adverse events/effects
Primary endpoint: Treatment readiness
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Cough during anesthesia emergence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >=Lower Limit of Quantitation (LLOQ)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Participants Reporting Adverse Events (AEs) Within 30 Days After Vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants Reporting Serious Adverse Events (SAEs), Medically Attended Adverse Events (MAEs) and Newly Diagnosed Chronic Medical Condition (NDCMCs) Within 30 Days After Vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Bone density enhancement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual assessment of lesion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Affective Lability
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of Subjects Reporting Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Change of Cormack Lehane grade
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Anti-DEN3 neutralizing antibody levels
Endpoint domain: Physiological/clinical
Primary endpoint: Adequate glycaemic control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Depression Clinical Remission
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Fluid balance volume at 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vasopressor therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from WhoQol-Bref at 8 weeks
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change from WhoQol-Bref at 16 weeks
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Number of Participants With Positive Serum Erythropoietin (EPO) Antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Total Number of Participants Who Experienced Acute Treatment Related Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Clinical recovery
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Self-administration of injections
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: MRI enhancing lesion frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Detection of at least one adenoma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Percentage of visualized mucosa
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: LARS Score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Mean Change in Dysphagia Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reactogenicity evaluations (REs)
Endpoint domain: Adverse events/effects
Primary endpoint: Maximal inspiratory mouth pressure (PImax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Sniff nasal inspiratory pressure (SNIP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Maximal expiratory mouth pressure (PEmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Visual Analog Score change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in oral hygiene
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and Tolerability of Preemptive Anidulafungin
Endpoint domain: Adverse events/effects
Primary endpoint: Reproducible bladder contraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Repeatability of corneal scans
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Posaconazole plasma levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficiency of priority assignment
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: accuracy of a predictable classifier from MCI to AD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in lip wrinkles from baseline to 1 month
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in lip wrinkle from baseline to 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in the lip wrinkles from baseline to 6 month
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Trinity Amputation Prosthesis Experience Scale (TAPES)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in fundamental motor skills (FMS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in children's physical activity
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Existence of significant fibrosis and cirrhosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Occurrence of SAE
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence of abnormal changes of laboratory measures
Endpoint domain: Adverse events/effects
Primary endpoint: Pharmacokinetic parameter of TPN171H:Tmax
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetic parameter of TPN171H:Cmax
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetic parameter of TPN171H:T1/2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetic parameter of TPN171H:AUC0-t
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response to treatment (modRECIST)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Spinal Structure and Mobility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fugl Meyer impairment scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Modified Rodnan Skin thickness score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Number of Participants With Undetectable HCV RNA at 12 Weeks Post End of Treatment (SVR12)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in intestinal microbiome diversity in allergic vs non-allergic pregnant mothers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in intestinal microbiome diversity in infants born from allergic vs non-allergic mothers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in intestinal microbiome diversity in infants at three months from allergic vs non-allergic mothers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in intestinal microbiome diversity in infants at six months from allergic vs non-allergic mothers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in intestinal microbiome diversity in infants at one year from allergic vs non-allergic mothers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total dose of fentanyl consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Migraine pain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Insulin-like Growth Factor-1 (IGF-1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Changes in IGF Binding Proteins (IGFBP-1, IGFBP-3)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Changes in Acid Labile Subunit (ALS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Magnitude and frequency of immune responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: HIV-1 viral load (RNA & DNA) in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Minimum plasma drug concentration (Cmin)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cecal colon insertion time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: RCB rate of 0-1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Cerebral oxygen desaturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: 3-year Disease-free survival
Endpoint domain: Mortality/survival
Primary endpoint: Stress alleviation
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Inflammation quenching
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with treatment success determined by a negative RT PCR for COVID19
Endpoint domain: Mortality/survival
Primary endpoint: Number of participants with adverse effects determined by the existence of the pharmacological side effects of the particular drug during treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Percent of Correctly-Identified Speech Materials
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent of Correctly-Identified Stimuli Characteristics when Two or More Stimuli are Presented
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physical activity recovery rate
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Immediate safety evaluation
Endpoint domain: Adverse events/effects
Primary endpoint: complete clearance rate of the CBD stones
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Hospitalisation for a cardiovascular event
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportions of Treg and NK cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: injury incidence
Endpoint domain: Adverse events/effects
Primary endpoint: Percent change in Hamilton Depression Scale (HamD17)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in composite cardiovascular risk score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of patients with positive Cutibacterium acnes sample
Endpoint domain: Adverse events/effects
Primary endpoint: Hematologic engraftment rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: deterioration of kidney function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Biochemically-verified smoking cessation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Follow-Up Completion Rate
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Severity of chronic venous insufficiency symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentage of patients who achieve complete response (CR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: percentage of patients who achieve partial response (PR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Successful breast reconstruction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Plasma levels of ketoconazole
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visibility of the Inversion Indicator
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rates of surgical site infection
Endpoint domain: Adverse events/effects
Primary endpoint: Cerebrospinal fluid biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pharmacokinetic profile of aliskiren
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Skin Reaction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: MRI diagnosis accuracy of cephaloceles
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Device Related Serious Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: No Distant Metastatic Disease at 1 Year
Endpoint domain: Mortality/survival
Primary endpoint: Success of transplantation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inhaler preference based on steps needed
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Incidence of 5-day rebleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: occurrence of urinary tract cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: occurrence of bladder cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: occurrence of renal cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Neurohormonal plasma concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Hospitalization decisions
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Change in AzBio Sentence test score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Geometric Mean Titer (GMT) Against A/H1N1, B/Victoria and B/Yamagata Vaccine Strains
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Seroconversion Rates (SCR) Against A/H1N1, B/Victoria and B/Yamagata Vaccine Strains
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Geometric Mean Titer (GMT) Against A/H3N2 Vaccine Strain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Seroconversion Rates (SCR) Against A/H3N2 Vaccine Strain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of participants with adverse events and treatment-emergent adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in physical examination, body weight, vital signs and laboratory parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and tolerability (erythema, swelling, degree of itching, and present pain intensity at injection site by measuring diameter and qualitative assessment)
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of delivery within 2 days from start of IMP administration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Incidence of delivery within 7 days from start of IMP administration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Incidence of delivery before 37 weeks of GA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Time to delivery measured from start of IMP administration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: AV-node escape rhythm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: bundle branch blocks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of CD133+ Cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Percent of CD34+ Cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Changes in fasting and postprandial plasma levels of appetite related hormones
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Post Op EOS measurements for alignment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Completion of biometric screening
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Doubling of serum Creatinine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Increase in serum Creatinine to 6.0 mg/dl or more
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Endstage renal disease (ESRD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Immune response variability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change from Baseline - Global Health Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Posterior Capsule Opacification
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Percentage of Participants With Complete Response 12 Weeks After PDT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency and severity of upper GI symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Overall patient's discomfort
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Fold Change in Serum N-telopeptides From Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Complications
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence Rate of ADRs Based on Baseline Characteristics of the Participants
Endpoint domain: Adverse events/effects
Primary endpoint: Change From Baseline in Symptoms of Parkinson's Disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Regional Nodal Failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Depression symptoms (PHQ-9 questionnaire)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Depression symptoms (CES-D questionnaire)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Depression/anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Difference in deconjugated bile acids in the blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Vineland Adaptive Behavior Scales
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Aberrant Behavior Checklist
Endpoint domain: Adverse events/effects
Primary endpoint: Identification of monocyte-based biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Identification of urine-based biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in Severity of Panic Disorder
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Asthma Control Based on Rescue Medication Use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Output of unformed stools
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Overall Survival (OS) Status
Endpoint domain: Mortality/survival
Primary endpoint: Overall Survival (OS) Median Duration
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of patients with serious adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of patients with adverse drug reactions (ADRs)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants Who Achieve a PPPASI-50
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Proportion of participants successfully withdrawn from levothyroxine treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes